A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy

Author： Chen Wei   Bepler Gerold  

Publisher： MDPI

E-ISSN： 2075-4426|3|3|251-262

ISSN： 2075-4426

Source： Journal of Personalized Medicine, Vol.3, Iss.3, 2013-09, pp. : 251-262

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents

By  

Chemotherapy, Vol. 62, Iss. 4, 2017-05 ,pp. : 239-245

Karger

Access to resources Recommend Favorite

Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy

By  

Chemotherapy, Vol. 62, Iss. 4, 2017-04 ,pp. : 205-213

Karger

Access to resources Recommend Favorite

Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results

By  

Chemotherapy, Vol. 60, Iss. 5-6, 2015-0 ,pp. : 294-299

Karger

Access to resources Recommend Favorite

Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer

By  

Chemotherapy, Vol. 57, Iss. 2, 2011-03 ,pp. : 147-155

Karger

Access to resources Recommend Favorite

A Phase II Study Directed by a Clinical Pathway for Carboplatin and Weekly Paclitaxel in Previously Untreated Patients with Unresectable Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 56, Iss. 1, 2010-02 ,pp. : 39-45

Karger

Access to resources Recommend Favorite